Medical Journals and the Pharmaceutical Industry

Seoul 25 March 2008

Mark Robertson

Publishing Director Asia-Pacific



Agenda

Clinical trials and publication planning

Editorial/publishing strategies

Guide lines



Phases of Clinical Studies/Trials

Phase 1

Researchers test an experimental drug or treatment in a small group of people (20-80) for the first time.

- -To evaluate its safety
- -To determine a safe dosage range -To identify side effects

Phase 2

The experimental study drug or treatment is given to a larger group of people (100-300).

- To see if it is effective
- To further evaluate its safety

Phase 3

The experimental study drug or treatment is given to large groups of people (1,000-3,000).

- -To confirm its effectiveness
- -To monitor side effects
- -To compare it to commonly used treatments
- -To collect information that will allow the experimental drug or treatment to be used safely

Phase 4

Post marketing studies delineate additional information including the drug's risks, benefits, and optimal use

Source: www.ClinicalTrials.gov – A service of the U.S. National Institutes of Health (NIH), through its National Library of Medicine (NLM), has developed this site in collaboration with the Food and Drug Administration (FDA).



Strategic comunication planning

= "gaining **product adoption and usage** through systematic, planned dissemaination of key messages and data to appropriate target audiences at the optimum time using the most effective communication channels" (Pharmaceutical Executive, A Guide to Strategic Communication Planning)

PLANNING

Analysis

Target/Objectives

Strategy

Customer needs

Information/data creation

Information/data dissemination



Publications

Journal reviews

Symposia

Workshops

Advisory boards

Abstracts

Educational materials/PR





How does the industry plan?

- The pharmaceutical industry often draws together a publication planning team of pre-clinical, medical, communications and marketing personnel to identify opportunities and co-ordinate the dissemination of data.
- For most products, the publication planning team will be set at a global level with the remit to translate data into publications for the markets.
- Often an external agency acts as a buffer and a facilitator.



Publication Planning Strategies

Innovators: 10 – 20 international KOLs

Early adopters: 30 – 50 national and regional KOLs Early majority broad audience: 200-300

Expanded target audience exposure: 1000-5000

1-11

Advisory board

- Key consultants
- Investigator meetings
- •Develop key messages & vocabulary
- Primary Publication/ Disease Review

Ш

Investigator meetings

- National & regional Advisory board
- •CME national/regional symposia
- •CME speaker programme
- Primary publications & supplements

Launch

Investigator meetings

- ·National & regional Advisory board
- PhaseIIIb/IV trials
- Launch activities
- •National & regional Symposia
- Regional workshops
- Field-based education
- Positioning reviews

IV/Post Launch

- PhaseIIIb/IV trials
- Advisory boards
- Key consultants
- Investigator meetings
- •National & regional Symposia
- Regional workshops
- ·Field-based education
- Phase IIb/IV publications, reviews and supplements

Source: European Pharmaceutical Executive



Agenda

Clinical trials and publication planning

Editorial/publishing strategies

Guide lines



Clinical trials

Seventy-five per cent of trials published in four of the five major medical journals (The Lancet, New England Journal of Medicine, Journal of the American Medical Association, Annals of Internal Medicine) are sponsored by the pharmaceutical industry. In the fifth journal, the BMJ, it is 30 per cent.

Source: http://news.independent.co.uk/uk/health_medical/story.jsp?story=514316 23apr04

Merck: Today, publications = our "currency"

Merck scientists published ~ 1000 articles in 2003

Laurence Hirsch, MD Merck Research Laboratories Publication Planning and Execution Excellence June 16, 2005 London



Phase I, II and III

Research articles



Top class journals

High impact factor

Excellent reputation

The right circulation





Reliability

Quick decision

Clear timelines

Published on schedule





Speed

Fast time to acceptance

Fast peer review

Fast publication





Communication

Clear aims and scope

Accessible editor

Manuscript tracking

Early proofs and reprints





Reprints

PUSH

High quality, appropriate papers from industry





PULL





High value reprints, paper and now online too

£

£

Phase I, II and III

- Research articles
- Readers
- Citations
- Revenue




Phase III, launch, post launch

- Supplements
- Review articles
- Advertising
- Readers
- Citations
- Revenue



The cycle continues





Agenda

Clinical trials and publication planning

Editorial/publishing strategies

Guide lines



Guidelines

- Readers
- Citations
- Revenue



Thank you

Seoul 25 March 2008

Mark Robertson

Publishing Director Asia-Pacific

